CUE - Company ID 0001645460
Cue Biopharma, Inc. trades as CUE. In its fiscal 2025 annual report the company posted revenue of $27.47M, up 195.7% from the prior year and net income of -$26.60M. This page tracks Cue Biopharma, Inc. through 496 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 7 fiscal years Cue Biopharma, Inc.'s revenue grew from $1.14M to $27.47M, a compound annual growth rate of 57.5%. Net profit margin expanded from -3411.5% to -96.9% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Proxy statement | DEF 14A | 2026-05-21 |
| D | - | 2026-05-14 |
| Major company event | 8-K | 2026-05-14 |
| Quarterly report | 10-Q | 2026-05-14 |
| PRE 14A | - | 2026-05-11 |
| New insider ownership | 3 | 2026-05-07 |
| Insider trade | 4 | 2026-05-07 |
| Employee stock plan | S-8 | 2026-05-01 |
The largest companies sharing Cue Biopharma, Inc.'s SEC industry classification (pharmaceutical preparations).
Cue Biopharma, Inc. reported revenue of $27.47M for fiscal year 2025, an increase of 195.7% year over year.
In its latest fiscal year Cue Biopharma, Inc. reported a net loss of $26.60M.